Prompt Gamma Time Imaging: a new medical-imaging modality for adaptive Particle Therapy
The project aims to enhance particle therapy efficacy and safety by developing Prompt Gamma Time Imaging for real-time monitoring of treatment, improving dose control and adaptive dosimetry.
Projectdetails
Introduction
Particle Therapy (PT) is potentially the most conformal and selective form of radiotherapy, but its clinical outcome is still limited, mainly because of the numerous sources of uncertainties affecting both treatment planning and delivery. The objective technical complexity of predicting and verifying the ion path in the patient has led to conservative treatments that, in order to increase safety, sacrifice efficacy.
Potential Benefits of Particle Therapy
Having full control of the dose gradient within the patient in real time would allow for fully exploiting the ballistic advantage of PT. The healthy-tissue sparing effect can be enormous, further encouraging the use of PT for paediatric malignancies. Alternatively, the target dose could be increased to achieve better tumour control, and dose escalation procedures could be envisaged to treat radio-resistant tumours.
Proposed Solution
With the aim of increasing both safety and efficacy, I propose a new medical-imaging modality to monitor PT treatments in real-time. It exploits the signal of secondary prompt gamma-rays emitted from nuclear interactions in the patients to recover information on:
- Ion range
- Tissue density
- Dose
I refer to this technique as Prompt Gamma Time Imaging (PGTI).
Development of PGTI
An original reconstruction algorithm and a dedicated detector will be developed to prove the clinical advantages of PGTI and bring this technique to the doorsteps of its clinical application. I will develop models to correlate the images provided by PGTI to real-time dose distributions, in order to enable the use of this technique for adaptive dosimetry.
Future Applications
PGTI will also be explored as a potential approach to proton tomography. For the first time, it would be possible to control the uncertainties affecting both treatment planning and treatment delivery with a unique device. PGTI may be the missing step towards the birth of image-guided particle therapy.
Financiële details & Tijdlijn
Financiële details
Subsidiebedrag | € 1.498.969 |
Totale projectbegroting | € 1.498.969 |
Tijdlijn
Startdatum | 1-10-2022 |
Einddatum | 30-9-2027 |
Subsidiejaar | 2022 |
Partners & Locaties
Projectpartners
- CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE CNRSpenvoerder
- CENTRE ANTOINE LACASSAGNE
Land(en)
Vergelijkbare projecten binnen European Research Council
Project | Regeling | Bedrag | Jaar | Actie |
---|---|---|---|---|
Gamma-Neutron Vision aimed at improved cancer treatments in Hadron TherapyThis project aims to develop a portable device for simultaneous gamma-ray and thermal neutron imaging to enhance ion-range verification and secondary neutron dose assessment in proton therapy. | ERC Proof of... | € 150.000 | 2024 | Details |
Portal Range Monitoring in Mixed Ion Beam SurgeryPROMISE aims to revolutionize carbon ion radiotherapy by developing mixed ion beams for real-time tumor monitoring, enhancing treatment precision and potentially improving patient outcomes. | ERC Consolid... | € 2.000.000 | 2024 | Details |
Cherenkov light for total-body Positron Emission TomographyThe project aims to develop a cost-effective, high-performance PET scanner using Cherenkov photon detection to enhance early cancer diagnosis and treatment monitoring. | ERC Proof of... | € 150.000 | 2023 | Details |
Advanced imaging system for Medical ApplicationsThe i-TED project aims to demonstrate the applicability of a gamma-ray imaging system in intraoperative Radio-Guided Surgery and neutron dose assessment in boron-neutron capture therapy. | ERC Proof of... | € 150.000 | 2023 | Details |
Towards pediatric molecular imaging: development of a low-dose and high-performance Total Body PET scannerDeveloping the PHOENIX total body PET scanner aims to enhance pediatric imaging by achieving high sensitivity and spatial resolution while ensuring patient safety and comfort. | ERC Starting... | € 1.464.841 | 2024 | Details |
Gamma-Neutron Vision aimed at improved cancer treatments in Hadron Therapy
This project aims to develop a portable device for simultaneous gamma-ray and thermal neutron imaging to enhance ion-range verification and secondary neutron dose assessment in proton therapy.
Portal Range Monitoring in Mixed Ion Beam Surgery
PROMISE aims to revolutionize carbon ion radiotherapy by developing mixed ion beams for real-time tumor monitoring, enhancing treatment precision and potentially improving patient outcomes.
Cherenkov light for total-body Positron Emission Tomography
The project aims to develop a cost-effective, high-performance PET scanner using Cherenkov photon detection to enhance early cancer diagnosis and treatment monitoring.
Advanced imaging system for Medical Applications
The i-TED project aims to demonstrate the applicability of a gamma-ray imaging system in intraoperative Radio-Guided Surgery and neutron dose assessment in boron-neutron capture therapy.
Towards pediatric molecular imaging: development of a low-dose and high-performance Total Body PET scanner
Developing the PHOENIX total body PET scanner aims to enhance pediatric imaging by achieving high sensitivity and spatial resolution while ensuring patient safety and comfort.
Vergelijkbare projecten uit andere regelingen
Project | Regeling | Bedrag | Jaar | Actie |
---|---|---|---|---|
REAL TIME MOLECULAR IMAGER WITH UNSURPASSED RESOLUTIONRETIMAGER aims to revolutionize PET imaging by achieving ten-fold improvements in spatial and temporal resolution, enabling real-time, high-sensitivity imaging for personalized precision medicine. | EIC Pathfinder | € 3.126.347 | 2023 | Details |
NEXT GENERATION IMAGING FOR REAL-TIME DOSE VERIFICATION ENABLING ADAPTIVE PROTON THERAPYThe NOVO project aims to develop a groundbreaking real-time dose verification technology for proton radiotherapy, enhancing personalized cancer treatment and improving patient outcomes. | EIC Pathfinder | € 3.759.489 | 2024 | Details |
Treatment planning assessment for the Optiflux radiosurgery systemDit project ontwikkelt een innovatieve radiotherapie met sub-MeV X-stralen voor nauwkeurige tumorbehandeling en minder schade aan omliggende organen. | Mkb-innovati... | € 20.000 | 2021 | Details |
Next generation Limited-Angle time-of-flight PET imagerThe PetVision project aims to develop a cost-effective, modular PET imaging device with enhanced sensitivity to improve cancer diagnostics accessibility across various medical settings. | EIC Pathfinder | € 3.374.041 | 2023 | Details |
Development of innovative proton and neutron therapies with high cancer specificity by 'hijacking' the intracellular chemistry of haem biosynthesis.NuCapCure aims to develop novel cancer treatments for glioblastoma by utilizing custom-made drugs through biosynthesis to enhance proton and neutron therapies for better targeting and efficacy. | EIC Pathfinder | € 5.972.875 | 2024 | Details |
REAL TIME MOLECULAR IMAGER WITH UNSURPASSED RESOLUTION
RETIMAGER aims to revolutionize PET imaging by achieving ten-fold improvements in spatial and temporal resolution, enabling real-time, high-sensitivity imaging for personalized precision medicine.
NEXT GENERATION IMAGING FOR REAL-TIME DOSE VERIFICATION ENABLING ADAPTIVE PROTON THERAPY
The NOVO project aims to develop a groundbreaking real-time dose verification technology for proton radiotherapy, enhancing personalized cancer treatment and improving patient outcomes.
Treatment planning assessment for the Optiflux radiosurgery system
Dit project ontwikkelt een innovatieve radiotherapie met sub-MeV X-stralen voor nauwkeurige tumorbehandeling en minder schade aan omliggende organen.
Next generation Limited-Angle time-of-flight PET imager
The PetVision project aims to develop a cost-effective, modular PET imaging device with enhanced sensitivity to improve cancer diagnostics accessibility across various medical settings.
Development of innovative proton and neutron therapies with high cancer specificity by 'hijacking' the intracellular chemistry of haem biosynthesis.
NuCapCure aims to develop novel cancer treatments for glioblastoma by utilizing custom-made drugs through biosynthesis to enhance proton and neutron therapies for better targeting and efficacy.